These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future? Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746 [TBL] [Abstract][Full Text] [Related]
6. Are we misunderstanding beta-blockers. Cruickshank JM Int J Cardiol; 2007 Aug; 120(1):10-27. PubMed ID: 17433471 [TBL] [Abstract][Full Text] [Related]
7. The role of β-blockers in the management of hypertension: an Asian perspective. Tomlinson B; Dalal JJ; Huang J; Low LP; Park CG; Rahman AR; Reyes EB; Soenarta AA; Heagerty A; Follath F Curr Med Res Opin; 2011 May; 27(5):1021-33. PubMed ID: 21410302 [TBL] [Abstract][Full Text] [Related]
8. Beta-blockers in hypertensive and coronary heart disease. Goldstein S Arch Intern Med; 1996 Jun; 156(12):1267-76. PubMed ID: 8651834 [TBL] [Abstract][Full Text] [Related]
9. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338 [TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Bangalore S; Parkar S; Grossman E; Messerli FH Am J Cardiol; 2007 Oct; 100(8):1254-62. PubMed ID: 17920367 [TBL] [Abstract][Full Text] [Related]
12. Optimizing treatment of diabetes and cardiovascular disease with combined alpha,beta-blockade. Bell DS Curr Med Res Opin; 2005 Aug; 21(8):1191-200. PubMed ID: 16083528 [TBL] [Abstract][Full Text] [Related]
13. [Do beta-blockers have a role in the modern treatment of arterial hypertension?]. Horký K Vnitr Lek; 1996 Jun; 42(6):420-5. PubMed ID: 8928415 [TBL] [Abstract][Full Text] [Related]
14. One size does not fit all: the role of vasodilating beta-blockers in controlling hypertension as a means of reducing cardiovascular and stroke risk. Basile JN Am J Med; 2010 Jul; 123(7 Suppl 1):S9-15. PubMed ID: 20609697 [TBL] [Abstract][Full Text] [Related]
16. Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. Bangalore S; Wild D; Parkar S; Kukin M; Messerli FH J Am Coll Cardiol; 2008 Sep; 52(13):1062-72. PubMed ID: 18848139 [TBL] [Abstract][Full Text] [Related]
17. Are tolerability concerns a class effect of beta-blockers in treating patients with hypertension? Kountz DS Postgrad Med; 2009 Jan; 121(1):14-24. PubMed ID: 19179810 [TBL] [Abstract][Full Text] [Related]
18. [Beta-adrenergic receptor blockers in clinical practice]. Czuriga I; Edes I Orv Hetil; 2004 Sep; 145(38):1951-60. PubMed ID: 15535106 [TBL] [Abstract][Full Text] [Related]
19. [Present trends and controversies in the use of beta-blockers in cardiovascular diseases]. Spoladore R; Fragasso G; Montanaro C; Maranta F; Torlasco C; Gerosa S; Margonato A Recenti Prog Med; 2010 Nov; 101(11):429-41. PubMed ID: 21197763 [TBL] [Abstract][Full Text] [Related]
20. Factors associated with the discontinuation of evidence-based cardiovascular therapies in patients with stable coronary artery disease: a primary care perspective. Mostaza JM; Lahoz C; Martín-Jadraque R; Sanmartín MA; Vicente I; Tranche S; Taboada M; Mantilla T; Monteiro B; Sanchez-Zamorano MA; Eur J Cardiovasc Prev Rehabil; 2009 Feb; 16(1):34-8. PubMed ID: 19237995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]